AUR1545

Overview

AUR1545 is a selective KAT2A / KAT2B (( GCN5/PCAF )) PROTAC degrader that induces monocyte differentiation and inhibits the growth of acute myeloid leukemia cells. AUR1545 inhibits cell growth, induces epithelial differentiation and suppresses tumor growth in small cell lung cancer models. AUR1545 inhibits cell growth and induces differentiation in neuroendocrine prostate cancer cells and primary patient-derived organoids. AUR1545 is applicable to research related to acute myeloid leukemia, small cell lung cancer and neuroendocrine prostate cancer . (Pink: GCN5/PCAF ligand ( HY-W1122565 ); Blue: Cereblon ligand ( HY-138793 ); Black: linker).

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Histone Acetyltransferase

Product Information

• Catalog No.: HY-173158
• CAS No.: 3031593-79-7
• Molecular Formula: C41H50BrN9O5
• Molecular Weight: 828.80
• Purity: 99.58%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (6.03 mM); Clear solution
• Availability: In-stock

Source

Original product source